South Korea treating adults treating kids screen time research and news South Korea

Study: Video Game Addiction Prevalent in Young Adults with ADHD

Reading now: 985
www.additudemag.com

June 12, 2023Young adults with ADHD are more likely to meet the criteria for Internet gaming disorder (IGD) or gaming disorder (GD) than are people without the condition, according to a new study published in the Journal of Attention Disorders.1The study’s findings revealed many insights on video game addiction: More than half (59%) of the participants with IGD also had ADHD.

Almost three-quarters of study participants with ADHD had IGD, compared to 30% among participants without ADHD. A staggering 82% of individuals with GD had ADHD, whereas just 21% of participants without GD had ADHD.

More than half of the participants with ADHD (57%) had GD.The study compared data collected over two years on gaming patterns and accompanying comorbidities, such as ADHD, between 136 clinical and 165 general gamer groups based in South Korea.

Read more on additudemag.com
The website mental.guide is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles

additudemag.com
75%
145
LSD, MDMA, Magic Mushrooms Clinical Trial Guidelines Released by FDA
July 7, 2023The Food and Drug Administration (FDA) has issued its first-ever draft guidance for clinical trials of psychedelic drugs to treat conditions including depression, mood disorders, anxiety, post-traumatic stress disorder, and substance use disorder.The guidance aims to address the unique challenges inherent in testing “classic psychedelics,” such as psilocybin (magic mushrooms) and lysergic acid diethylamide (LSD), and “entactogens” or “empathogens,” such as methylenedioxymethamphetamine (MDMA) for treating psychiatric conditions that failed to respond to other therapies. The FDA recommends clinical trial considerations regarding subject safety, data collection, manufacturing controls, and drug application requirements.Ultimately, “the goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications,” said Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, in a statement last month.In February 2022, researchers from Johns Hopkins Medicine reported that psilocybin-assisted therapy for major depressive disorder produced antidepressant effects up to 12 months after treatment.1Ari Tuckman, Psy.D., and Stephanie Sarkis, Ph.D., recently told ADDitude that using very low (micro) doses of psychedelics, such as LSD and psilocybin is gaining renewed attention as a treatment for anxiety and depression.
DMCA